Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone), published as a clinical trial.

L-692,429, a substituted benzolactam, is a novel nonpeptide mimic of the GH secretagogue, GH-releasing peptide-6.

The GH peak was seen 30-45 min after initiation of the infusion.

Who Took Part

The study group was 3 subjects.

By PubMed's age tags, the people studied were teenagers and adults, men only.

How the Study Was Run

In design terms this was a double-blind and placebo-controlled study.

Neither the subjects nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Benzazepines, Growth Hormone, Growth Hormone-Releasing Hormone, Hormones, Hydrocortisone, Oligopeptides and Osmolar Concentration.

What This Means in Plain Language

The paper is a double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 3 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1993 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.